Article
XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling.
British journal of haematology - 1 Nov 2023
Moia Riccardo, Terzi di Bergamo Lodovico, Talotta Donatella, Bomben Riccardo, Forestieri Gabriela, Spina Valeria, Bruscaggin Alessio, Cosentino Chiara, Almasri Mohammad, Dondolin Riccardo, Bittolo Tamara, Zucchetto Antonella, Baldoni Stefano, Del Giudice Ilaria, Mauro Francesca Romana, Maffei Rossana, Chiarenza Annalisa, Tafuri Agostino, Laureana Roberta, Del Principe Maria Ilaria, Zaja Francesco, D'Arena Giovanni, Olivieri Jacopo, Rasi Silvia, Mahmoud Abdurraouf, Al Essa Wael, Awikeh Bassel, Kogila Sreekar, Bellia Matteo, Mouhssine Samir, Sportoletti Paolo, Marasca Roberto, Scarfò Lydia, Ghia Paolo, Gattei Valter, Foà Robin, Rossi Davide, Gaidano Gianluca
Abstract excerpt
Here we evaluated the epigenomic and transcriptomic profile of XPO1 mutant chronic lymphocytic leukaemia (CLL) and their clinical phenotype. By ATAC-seq, chromatin regions that were more accessible in XPO1 mutated CLL were enriched of binding sites for transcription factors regulated by pathways emanating from the B-cell receptor (BCR), including NF-κB signalling, p38-JNK and RAS-RAF-MEK-ERK. XPO1 mutant CLL,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.